TSX gains after CPI shows US inflation rose 3%
Arcutis Biotherapeutics Inc. (ARQT) stock reached a 52-week high of 21.3 USD, marking a significant milestone for the company. The biopharmaceutical company, now valued at $2.55 billion, demonstrates impressive financial metrics with a robust gross profit margin of 89.1% and substantial revenue growth of 99.5% over the last twelve months. Over the past year, the stock has experienced a remarkable 114.9% increase, reflecting strong investor confidence and positive market performance. According to InvestingPro analysis, the company appears fairly valued at current levels, with a healthy liquidity position reflected in its current ratio of 3.2. This surge in stock price underscores Arcutis Biotherapeutics’ progress and potential in the biopharmaceutical industry. The achievement of a 52-week high highlights the company’s ongoing growth and strategic advancements, positioning it favorably in the competitive market landscape. With a beta of 2.06, investors should note the stock’s higher volatility compared to the market. InvestingPro offers 11 additional investment tips and a comprehensive analysis report for ARQT, helping investors make informed decisions.
In other recent news, Arcutis Biotherapeutics has received approval from the U.S. Food and Drug Administration for its ZORYVE cream, specifically for treating mild to moderate atopic dermatitis in children aged 2 to 5 years. This approval offers a non-steroidal treatment option that can be used for any duration, providing an alternative to topical steroids for young children. In addition, Arcutis Biotherapeutics is seeking to expand the use of ZORYVE cream for treating plaque psoriasis in children as young as 2 years old, which would make it the first topical PDE4 inhibitor for this age group if approved. Meanwhile, Mizuho has raised its price target for Arcutis Biotherapeutics to $26 from $21, maintaining an Outperform rating, citing increased sales forecasts for the ZORYVE franchise. The research firm now projects ZORYVE sales to reach approximately $89 million for the third quarter of 2025. In related news, David W. Osborne, a co-founder of Arcutis Biotherapeutics, has been appointed as Chief Innovation Officer at Palvella Therapeutics. Osborne, who has a significant background in developing topical therapies, contributed to the development of ZORYVE cream. These developments highlight significant progress and strategic moves within Arcutis Biotherapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.